Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB), a clinical-stage company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. CEO Rand Sutherland will engage in a fireside chat on December 3, 2024, at 2:00 p.m. ET. The presentation will be accessible via live webcast in the 'Events' section of the company's website, with a replay available for 90 days afterward.
Details
News Market Reaction – UPB
The recorded move for UPB in the trading session of this news was -1.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio’s CEO, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 2:00 p.m. ET.
A live webcast of the presentation will be available under the “Events” tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.